乳腺癌中阿诺基斯相关基因的预后价值和免疫特征
Qing Wu1,2, Yang Luo1, Nan Lin3,4
1Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province, China.
Journal of immunotherapy (Hagerstown, Md. : 1997)
|June 12, 2024
概括
一个使用阿诺基斯相关基因 (ANRGs) 的新型9基因风险评分系统有效预测乳腺癌预后,并识别患有免疫抑制瘤微环境的患者,指导潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 乳腺癌的预后仍然难以准确预测.
- 与阿诺基斯相关的基因 (ANRGs) 在癌症的进展和转移中发挥着作用.
- 了解瘤微环境对于开发有效治疗方法至关重要.
研究的目的:
- 开发和验证基于ANRGs的乳腺癌预后模型.
- 研究风险得分与瘤免疫微环境之间的关联.
- 探索一个关键风险基因 (EPB41L4B) 在乳腺癌中的功能作用.
主要方法:
- 利用TCGA和GSE42568数据库中的转录组数据.
- 构建了一个9基因风险评分系统,并将患者分为高风险和低风险组.
- 进行了卡普兰-梅尔分析以预测存活率,并使用GSE7390.0验证了该模型.
- 通过体外实验分析瘤免疫透和基因功能.
主要成果:
- 一个9基因预后模型 (包括EPB41L4B,CXCL2,SLC7A5,SFRP1,SDC1,BHLHE41,SPINT1,KRT15,CD24) 准确地预测了高风险乳腺癌患者的低生存率.
- 高风险得分与免疫抑制性瘤微环境相关,包括较低的ESTIMATE得分和瘤透性淋巴细胞减少.
- 下调EPB41L4B抑制了细胞活力和迁移,同时促进乳腺癌细胞的亡.
结论:
- 基于9基因的ANRG模型是预测乳腺癌预后的可靠工具.
- 该模型可以识别患有免疫抑制瘤微环境的患者,并建议潜在的免疫治疗点.
- EPB41L4B在乳腺癌的进展中起着重要作用,可能是治疗点.
更多相关视频
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.7K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
